Kenneth J. Bender, PharmD, MA

Kenneth J. Bender, PharmD, MA

Posts by Author

A recent meta-analysis supports evidence of the effectiveness of the fixed olanzapine/fluoxetine combination (Symbyax) in treating the depressive phase of bipolar disorder. Response was ranked higher, but with no more adverse effects, than with treatment with olanzapine alone.

In a new study, "as needed" use of an opioid antagonist for heightened alcohol craving appeared to reduce the number of heavy drinking days and total amount of alcohol consumed.

Results of a 10-week prospective study, recently reported at the Annual Meeting of the American Association for Geriatric Psychiatry, offered no conclusive evidence about the mortality risk of elderly patients with Alzheimer disease who were treated with antipsychotics.

Given the likelihood that insufficient numbers of patients will be available for a randomized controlled trial of MAOIs in refractory depression or atypical depression, we must still rely on consensus guidelines and expert opinion.

The FDA Neurological Devices Panel met to consider the Agency’s proposal to reclassify cranial electrotherapy stimulator (CES) devices to Class III with premarket approval.

Much could be gained if an agreed minimum set of appropriate and important outcomes was measured and reported in all clinical trials in a particular area.

A new study examining conventional “start low, go slow” nutrition replenishment protocols for hospitalized patients with anorexia nervosa (AN) that have been recommended by professional organizations and it's outcomes.

A meta-analysis of the Omega-3 fatty acid EPA (eicosapentaenoic acid) as therapeutic supplement for major depression followed the above study online September 6 in the Journal of Clinical Psychiatry.

"I'm all over it, because I'm looking for something to help," declared Army Vice-Chief of Staff General Peter W. Chiarelli, quoted in USA Today News September 20, in his response to a study finding an increased risk of suicide in US military personnel with low Omega-3 fatty acid serum levels.

A depot antipsychotic regimen is less likely to be discontinued than an oral dosage form . . .


By clicking Accept, you agree to become a member of the UBM Medica Community.